Anthony Brown

Anthony Brown

Auto-generated profile, based on publicly available information

Anthony Brown

Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
ZLZhenhua Li
Zhenhua Li
HZHuanbin Zhao
Huanbin Zhao
WYWenjian Yang
Wenjian Yang
MMMaud Maillard
Maud Maillard
SYSatoshi Yoshimura
Satoshi Yoshimura
JYJun Yang
Jun Yang
ETV6::RUNX1 is the most common fusion gene in childhood acute lymphoblastic leukemia (ALL) associated with favorable prognosis, but the optimal therapy for this subtype remains unclear. Profiling the genomic and pharmacological landscape of 194 pediatric ETV6::RUNX1 ALL cases, we uncover two transcriptomic clusters, C1 (61%) and C2 (39%). Compared to C1, the C2 subtype features higher white blood cell counts and younger age at diagnosis, as well as better early treatment responses. Pharmacologically, C2 is more sensitive to thiopurines and prednisolone, partially explained by the enrichment of PAX5 deletions. Re-introducing PAX5 in ETV6::RUNX1 ALL of the C2 subtype converts its gene expression and drug resistance profile to C1, with partial blockade of G1 to S transition mediated by CDK6 expression. Our results point to molecular heterogeneity within ETV6::RUNX1 ALL linked to divergent drug responses, providing insights into the pathogenesis and therapeutic vulnerability of this common pediatric ALL subtype.

24 June 2024 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
SKShunsuke Kimura
Shunsuke Kimura
CPChun Shik Park
Chun Shik Park
LMLindsey E. Montefiori
Lindsey E. Montefiori
Ilaria IacobucciIlaria Iacobucci
Ilaria Iacobucci
PPPetri Pölönen
Petri Pölönen
CMCharles G Mullighan
Charles G Mullighan
Acute lymphoblastic leukemia expressing the gamma delta T-cell receptor (γδ T-ALL) is a poorly understood disease. We studied 200 children with γδ T-ALL from 13 clinical study groups to understand the clinical and genetic features of this disease. We found age and genetic drivers were significantly associated with outcome. γδ T-ALL diagnosed in children under 3 years of age was extremely high-risk and enriched for genetic alterations that result in both LMO2 activation and STAG2 inactivation. Mechanistically, using patient samples and isogenic cell lines, we show that inactivation of STAG2 profoundly perturbs chromatin organization by altering enhancer–promoter looping, resulting in deregulation of gene expression associated with T-cell differentiation. High-throughput drug screening identified a vulnerability in DNA repair pathways arising from STAG2 inactivation, which can be targeted by poly(ADP-ribose) polymerase inhibition. These data provide a diagnostic framework for classification and risk stratification of pediatric γδ T-ALL. Significance: Patients with acute lymphoblastic leukemia expressing the gamma delta T-cell receptor under 3 years old or measurable residual disease ≥1% at end of induction showed dismal outcomes and should be classified as having high-risk disease. The STAG2/LMO2 subtype was enriched in this very young age group. STAG2 inactivation may perturb chromatin conformation and cell differentiation and confer vulnerability to poly(ADP-ribose) polymerase inhibition.

8 March 2023 in Communications Biology
Verified
Journal Article
Open access
PDF file
ABAnthony Brown
Anthony Brown
QPQingfei Pan
Qingfei Pan
LFLi Fan
Li Fan
EIEmilie Indersie
Emilie Indersie
CTCheng Tian
Cheng Tian
LZLiqin Zhu
Liqin Zhu
Prognosis of children with high-risk hepatoblastoma (HB), the most common pediatric liver cancer, remains poor. In this study, we found ribonucleotide reductase (RNR) subunit M2 (RRM2) was one of the key genes supporting cell proliferation in high-risk HB. While standard chemotherapies could effectively suppress RRM2 in HB cells, they induced a significant upregulation of the other RNR M2 subunit, RRM2B. Computational analysis revealed distinct signaling networks RRM2 and RRM2B were involved in HB patient tumors, with RRM2 supporting cell proliferation and RRM2B participating heavily in stress response pathways. Indeed, RRM2B upregulation in chemotherapy-treated HB cells promoted cell survival and subsequent relapse, during which RRM2B was gradually replaced back by RRM2. Combining an RRM2 inhibitor with chemotherapy showed an effective delaying of HB tumor relapse in vivo. Overall, our study revealed the distinct roles of the two RNR M2 subunits and their dynamic switching during HB cell proliferation and stress response.

24 February 2023 in Oncogene
Verified
Journal Article
Open access
PDF file
CTCheng Tian
Cheng Tian
LLLiyuan Li
Liyuan Li
QPQingfei Pan
Qingfei Pan
BXBeisi Xu
Beisi Xu
YLYizhen Li
Yizhen Li
LZLiqin Zhu
Liqin Zhu
Intrahepatic cholangiocarcinoma (iCCA) is characterized by its highly desmoplastic stroma. Myofibroblasts (MFs) are present both within the tumor mass (intratumoral MFs, iMFs) and at the tumor border (peritumoral MFs, pMFs). Using a spheroid-based coculture system, we show that the initial iCCA-pMF contact is growth suppressive to the tumor cells. However, prolonged iCCA-pMF interaction elicits significant tumor cell invasion and dissemination. We find that vascular cell adhesion molecule-1 (Vcam1) level is elevated in tumor cells in contact with pMFs but low in disseminated tumor cells both in vitro and in vivo. A gene regulatory network analysis of mouse and patient iCCA tumors and Vcam1 knockout (Vcam1KO) demonstrate a heavy involvement of Vcam1 in epithelial-to-mesenchymal transition. While Vcam1KO has only a limited impact on tumor cell growth in their monoculture, Vcam1KO spheroids exhibit instant dissemination and a severe growth defect when cocultured with pMFs. When transplanted into the liver, Vcam1KO iCCA cells show a similar increase in dissemination but a significant defect in establishing primary and metastatic tumors. Incomplete blocking of Vcam1 in vivo reduces the size but increase the number of metastatic lesions. Overall, our study shows a spatiotemporal regulation of iCCA growth and dissemination by pMFs in a Vcam1-dependent manner.

28 July 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
BBBrennan P. Bergeron
Brennan P. Bergeron
KBKelly R. Barnett
Kelly R. Barnett
KBKashi Raj Bhattarai
Kashi Raj Bhattarai
RMRobert Jackson Mobley
Robert Jackson Mobley
BHBaranda S. Hansen
Baranda S. Hansen
DSDaniel Savic
Daniel Savic
Brennan P Bergeron, Kelly R Barnett, Kashi Raj Bhattarai, Robert Jackson Mobley, Jr., Baranda S Hansen, Anthony Brown, Kiran Kodali, Anthony Andrew High, Sima J